BerGenBio announces first patient dosed in BGB324 AML trial
5 November 2014 | By BerGenBio AS
BerGenBio AS announces that the first patient has been dosed in its multi-centre Phase 1b trial (BGBC003) of BGB324, a selective inhibitor of Axl, in patients with acute myeloid leukaemia (AML) at Haukeland University Hospital in Bergen, Norway...